UroToday - Consumption of Dietary Supplements and Over-The-Counter and Prescription Medications in Men Participating in the Prostate Cancer Prevention Trial at an Academic Center - Abstract

[Guest guest]

Seems they may not have been controlling for supplements in past trials.

Friday, 14 March 2008

Department of Internal Medicine, Division of Hematology and Oncology, Ohio

State University, Columbus, OH 43210, USA.

It is hypothesized that dietary patterns, individual nutrients, and specific

prescription and over-the-counter medications may influence prostate

carcinogenesis. Little information is available regarding the use of these

products among men who are participating in prevention trials targeting

prostate cancer.

A total of 92 men (mean age 69 years) participating in the Prostate Cancer

Prevention Trial (PCPT) at an academic center were asked to bring all

nutritional supplements and medications to regularly scheduled study visits.

Data were collected on 86 of 92 men. We found that 85% of men in the PCPT

regularly consumed at least 1 nutritional supplement. The mean (+/-standard

deviation) number of dietary supplements consumed per man was 3.3 +/- 3.5

(range 0-21). A multivitamin and multimineral (73%) supplement was the most

common product consumed. Single-nutrient supplements regularly consumed

included: vitamin E (48%), vitamin C (31%), calcium (24%), and selenium

(7%). Of men, 36% reported consumption of herbal products. Medications

frequently consumed during the study period that may influence prostate

carcinogenesis included nonsteroidal antiinflammatory drugs (57%),

antihypertensives (49%), lipid lowering agents (27%), and aspirin (64%).

Participants in the PCPT at an academic center have a high propensity for

dietary supplement use. Many, such as vitamin E and selenium, are

hypothesized to influence the risk of prostate cancer. Several of the

medications commonly consumed, including aspirin, nonsteroidal

antiinflammatory drugs, and statins, are being investigated as

chemopreventive agents. Investigators designing prostate cancer

chemoprevention trials should consider including detailed documentation of

exposure to these products that may influence study outcomes.

Written by

Grainger EM, Kim HS, Monk JP, Lemeshow SA, Gong M, Bahnson RR, Clinton SK.

Reference

Urol

Oncol.

2008 Mar-Apr;26(2):125-32.

doi:10.1016/j.urolonc.2007.01.016

PubMed

Abstract

PMID:18312929

=====================================================

For info on managing your subscription: http://ppml-info.org/welcome.html

Need more help? Send email to: prostate-request@...